Background: SARS-CoV-2 has been demonstrated to be inhibited by Remdesivir, a broad-spectrum antiviral medication. Remdesivir has been tried for a compassionate use in severe COVID-19 in the absence of any viable treatment for SARS-CoV-2 infection (COVID-19).
Methods: In 50 patients with SARSCoV-2 infection who were given Remdesivir as part of their institutional treatment plan, we conducted an observational prospective analysis. Remdesivir 100 mg was given daily for7 days during the therapy period. The results of liver and kidney function tests were compared before and after Remdesivir administration.
Results: With the administration of Re%) exhibited an improvement in their oxygen needs. Patients reported only a few minor side effects. Serious side effects, on the other hand, were rare.
Conclusion: Remdesivir seems to have an excellent safety profile, while its efficacy in the treatment of COVID-19 is currently inconclusive. Remdesivir use in patients was shown to be safe, with no serious side effects or significant changes in normal test results for liver and kidney functions.
Keywords: Adverse events, Covid-19, liver function, remdesivir, renal function